The Rainwater Prize - Breakthrough Prize for Effective Treatments in PSP Grant
Funding Amount
US $2,000,000 - US $10,000,000
Deadline
Deadline not published
Grant Type
Foundation
Can we apply?
Check your organization against each line. Taken from the listing; confirm with the funder's guidelines.
Other requirements
- This award may be awarded to individuals or teams of scientists.
Overview
The Rainwater Prize, established in 2018, aims to advance research in neurodegenerative diseases, particularly PSP. It recognizes significant contributions to effective treatments, with potential awards ranging from $2M to $10M based on treatment efficacy. Awardees, selected by a committee of leading scientists, may include individuals or teams, and the prize funds are intended for non-profit research purposes. This prestigious prize may or may not be awarded annually.
NOTE: This prize may or may not be awarded each year.
Launched in 2018, the Rainwater Prize Program was designed with the goals of:
- Increasing awareness of critical gaps in neurodegenerative research
- Attracting and retaining researchers to work on tauopathies
- Awarding scientific achievements that lead to new treatments for patients.
- Breakthrough Prize for Effective Treatments in PSP
- This prize recognizes investigator(s) whose work is considered a significant contribution to the development of effective treatments for PSP.
Awardees will be chosen by a committee of international scientific leaders from a wide range of fields and backgrounds. The awardee will be chosen based on their scientific contributions that ultimately led to the development of treatments for PSP, demonstrated willingness to collaborate and share scientific resources, leadership, mentorship, and overall contributions to the scientific community. This prize may or may not be awarded each year and may be awarded to individuals or teams of scientists.
Current Breakthrough Prize Categories:
- $2M – FDA approved treatment that meaningfully extends good quality of life for patients.
- $4M – FDA approved treatment that cures PSP early in progression.
- $10M – FDA approved treatment that prevents PSP and/or reverses disease damage.
While it is our hope that the prize money will be used to further the recipient’s neurodegenerative disease research, the prize recipient will only be able to use the funds for non-profit purposes.
Eligibility
This award may be awarded to individuals or teams of scientists.
What Rainwater Charitable Foundation actually gave
Source: IRS Form 990-PF, 2024
- Grants in 2024
- 320
- Total given
- $43.57M
- Median grant
- $50K
- Range
- $320–$3.32M
- By dollars: Texas 62%, California 10%, Illinois 6%. Top recipient cities: Fort Worth, TX; Dallas, TX; San Francisco, CA.
- 26% of grants with a stated purpose were for general or operating support.
- 25% of recipients were new grantees, not repeat recipients.
Example grants
Tarrant to & Through (T3) · Fort Worth, TX
Program support - college advising
$3.32M
Life Outreach International · Fort Worth, TX
Operations support
$3M
Citysquare · Dallas, TX
Operations support
$2M
Fort Worth Community Land Trust · Fort Worth, TX
Program support - carroll park
$2M
Alzheimer's Association · Chicago, IL
Medical research
$1.87M
Focus Areas & Funding Uses
Fields of Work
- Science research
- Alzheimer's
Categories
Browse similar grants by category
Related Grants
Open grants from this funder and similar programs
The Rainwater Prize - Outstanding Innovation in Neurodegenerative Research Grant
Rainwater Charitable Foundation
Amount
US $400,000
Deadline
Deadline not published
Tauopathy Challenge Workshop Grant
Rainwater Charitable Foundation
Amount
US $10,000 - US $510,000
Deadline
Deadline not published
The Rainwater Prize - Innovative Early-Career Scientists Grant
Rainwater Charitable Foundation
Amount
US $200,000
Deadline
Deadline not published
Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Varies
Deadline
November 10, 2026
Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
November 19, 2026
Alzheimer's Drug-Development Program (U01 Clinical Trial Optional)
National Institutes of Health
Amount
Up to $1,500,000
Deadline
November 5, 2027
Ready to apply for The Rainwater Prize - Breakthrough Prize for Effective Treatments in PSP Grant?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found The Rainwater Prize - Breakthrough Prize for Effective Treatments in PSP Grant. Now let's win it.